Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889186 | 0.94 | PAOX (0.50) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL8748159 | 0.94 | CASP2 (0.61) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL22694320 | 0.92 | CASP2 (0.59) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL8625858 | 0.91 | CASP2 (0.63) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL889215 | 0.89 | PAOX (0.48) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL889319 | 0.88 | CASP2 (0.71) | CASP2EPHX1CNR1NAAAFAAH | |
| Hexadecanoic Acid Propylamide SCHEMBL8394270 | 0.88 | FAAH (0.65) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL8398706 | 0.88 | FAAH (0.65) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL8397997 | 0.88 | FAAH (0.65) | CASP2EPHX1CNR1NAAAFAAH | |
| SCHEMBL8394921 | 0.88 | FAAH (0.65) | CASP2EPHX1CNR1NAAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | CASP2 2840/4885EPHX1 2839/4885CNR1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.